One of the largest API manufacturers in Asia, Aurobindo Pharma has notified that Aurobindo Pharma Australia Pty Limited, a wholly owned subsidiary of the company, has secured approval from Therapeutic Goods Administration (TGA), Government of Australia for the registration of Amlodipine Besylate Tablets 5mg and 10 mg.

Amlodipine Besylate Tablests falls under the Central Nervous System (CNS) therapeutic segment and is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients.

This is Aurobindo's fourth approval from TGA, Australia.

Aurobindo Pharma Limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.

The shares of the company closed at Rs 485 on BSE, up 2% compared to previous close of Rs 477.